Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
Radium-223 dichloride (Ra-223) is the first α-particle emitting radiopharmaceutical to be approved for the treatment of patients with castration-resistant prostate cancer and associated bone metastases, and the first bone-targeting agent to significantly improve patient overall survival whilst reduc...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Blackwell Publishing Ltd
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467240/ |